Related Links


BioFocus launches SilenceSelect microsite

BioFocus has recently launched its new microsite,, which is dedicated to the SilenceSelect® and FLeXSelect® adenoviral technology.

With the ability to knock-down or knock-in human genes in primary cells, these collections cover most of the druggable genome. Detailed information on both collections is available on the microsite, along with details of the adenovirus technology employed.

SilenceSelect consists of more than 11,500 small hairpin RNAs (shRNAs) that can be used to knock-down approximately 5000 different human druggable targets. All of the protein classes that are considered to be affected by small-molecule drugs are represented. FLeXSelect comprises a collection of more than 1900 full-length human complementary DNAs (cDNAs) that can be used to enhance the expression of specific genes within a cell. Using the properties of adenovirus vectors, the cDNA or shRNA is delivered into a wide range of targeted human primary cells. These collections, combined with BioFocus’s expertise in designing disease-relevant high-content and high-throughput screening assays, serve as the basis for target discovery and mechanism-of-action studies.

The microsite is updated daily with the latest contents of SilenceSelect and FLeXSelect, including the latest gene transcript information from The National Center for Biotechnology Information (NCBI).

Share this article

More services


This article is featured in:
Companies and People


Comment on this article

You must be registered and logged in to leave a comment about this article.